Catalyst Pharmaceuticals Revenue 2010-2025 | CPRX

Catalyst Pharmaceuticals revenue from 2010 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Catalyst Pharmaceuticals Annual Revenue
(Millions of US $)
2024 $492
2023 $398
2022 $214
2021 $141
2020 $119
2019 $102
2018 $1
2017 $0
2016 $0
2015 $0
2014 $0
2013 $0
2012 $0
2011 $0
2010 $0
2009 $0
Catalyst Pharmaceuticals Quarterly Revenue
(Millions of US $)
2025-03-31 $141
2024-12-31 $142
2024-09-30 $129
2024-06-30 $123
2024-03-31 $99
2023-12-31 $111
2023-09-30 $103
2023-06-30 $100
2023-03-31 $85
2022-12-31 $61
2022-09-30 $57
2022-06-30 $53
2022-03-31 $43
2021-12-31 $38
2021-09-30 $36
2021-06-30 $36
2021-03-31 $30
2020-12-31 $31
2020-09-30 $29
2020-06-30 $30
2020-03-31 $29
2019-12-31 $30
2019-09-30 $31
2019-06-30 $29
2019-03-31 $12
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $2.692B $0.492B
Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights to Firdapse (for treating LEMS) from BioMarin Pharmaceutical Inc. for its development and commercialization in the U.S. Firdapse is currently approved in the European Union and in the U.S. for treating of LEMS in adults. The company also plans to file a supplemental new drug application for Firdapse to treat pediatric patients with LEMS.?The company is also strengthening the commercial portfolio of Firdapse. It has already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population.?Apart from Firdapse, the company is working on a generic version of Lundbeck's Sabril, CPP-109, for the treatment of infantile spasms and complex partial seizures.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $85.929B 32.24
Zoetis (ZTS) United States $70.240B 26.21
Takeda Pharmaceutical (TAK) Japan $47.983B 9.54
Daiichi Sankyo, - (DSNKY) Japan $44.148B 22.63
BeOne Medicines - (ONC) Cayman Islands $29.241B 0.00
Sandoz Group AG (SDZNY) Switzerland $23.170B 0.00
Merck (MKKGY) Germany $16.905B 12.39
Summit Therapeutics (SMMT) United States $15.537B 0.00
Shionogi (SGIOY) Japan $14.870B 14.90
United Therapeutics (UTHR) United States $13.078B 11.57
Neurocrine Biosciences (NBIX) United States $12.685B 43.45
Orion OYJ (ORINY) Finland $10.469B 28.31
IPSEN (IPSEY) France $9.739B 0.00
Corcept Therapeutics (CORT) United States $8.141B 66.18
Stevanato Group S.p.A (STVN) Italy $7.447B 45.54
Madrigal Pharmaceuticals (MDGL) United States $6.327B 0.00
Ionis Pharmaceuticals (IONS) United States $6.309B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.153B 0.00
Grifols, S.A (GRFS) Spain $5.872B 0.00
Ono Pharmaceutical (OPHLF) Japan $5.031B 15.30
Soleno Therapeutics (SLNO) United States $4.242B 0.00
Crinetics Pharmaceuticals (CRNX) United States $2.897B 0.00
Hypermarcas (HYPMY) Brazil $2.850B 18.75
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.548B 13.78
BioCryst Pharmaceuticals (BCRX) United States $2.078B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.066B 0.00
Indivior (INDV) United States $1.919B 8.14
Centessa Pharmaceuticals (CNTA) United Kingdom $1.896B 0.00
ARS Pharmaceuticals (SPRY) United States $1.648B 0.00
Endo (NDOI) United States $1.595B 0.00
Evotec AG (EVO) Germany $1.449B 0.00
Ocular Therapeutix (OCUL) United States $1.448B 0.00
Guardian Pharmacy Services (GRDN) United States $1.304B 0.00
Dyne Therapeutics (DYN) United States $1.208B 0.00
Harrow (HROW) United States $1.163B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.088B 21.76
Enliven Therapeutics (ELVN) United States $1.038B 0.00
Verve Therapeutics (VERV) United States $0.996B 0.00
Collegium Pharmaceutical (COLL) United States $0.967B 5.22
Akebia Therapeutics (AKBA) United States $0.964B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.929B 0.00
Ardelyx (ARDX) United States $0.880B 0.00
Elite Pharmaceuticals (ELTP) United States $0.828B 0.00
Cronos Group (CRON) Canada $0.729B 0.00
Xeris Biopharma Holdings (XERS) United States $0.729B 0.00
Liminatus Pharma (LIMN) United States $0.694B 0.00
Xencor (XNCR) United States $0.589B 0.00
Altimmune (ALT) United States $0.583B 0.00
KalVista Pharmaceuticals (KALV) United States $0.582B 0.00
USANA Health Sciences (USNA) United States $0.572B 12.43
Amylyx Pharmaceuticals (AMLX) United States $0.571B 0.00
Relay Therapeutics (RLAY) United States $0.567B 0.00
Regulus Therapeutics (RGLS) United States $0.565B 0.00
Bioventus (BVS) United States $0.555B 14.08
Theravance Biopharma (TBPH) United States $0.534B 0.00
Zevra Therapeutics (ZVRA) United States $0.500B 0.00
AleAnna (ANNA) United States $0.484B 0.00
Siga Technologies (SIGA) United States $0.457B 9.55
Oruka Therapeutics (ORKA) United States $0.440B 0.00
Organogenesis (ORGO) United States $0.439B 0.00
Tourmaline Bio (TRML) United States $0.435B 0.00
Savara (SVRA) United States $0.394B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.334B 9.03
Heron Therapeutics (HRTX) United States $0.328B 0.00
Aquestive Therapeutics (AQST) United States $0.319B 0.00
Nektar Therapeutics (NKTR) United States $0.304B 0.00
Nature's Sunshine Products (NATR) United States $0.279B 25.59
Tonix Pharmaceuticals Holding (TNXP) United States $0.262B 0.00
Esperion Therapeutics (ESPR) United States $0.212B 0.00
MediWound (MDWD) Israel $0.211B 0.00
OmniAb (OABI) United States $0.209B 0.00
Nanobiotix S.A (NBTX) France $0.208B 0.00
Aldeyra Therapeutics (ALDX) United States $0.201B 0.00
Larimar Therapeutics (LRMR) United States $0.191B 0.00
ProKidney (PROK) United States $0.189B 0.00
Profound Medical (PROF) Canada $0.186B 0.00
4D Molecular Therapeutics (FDMT) United States $0.185B 0.00
Aclaris Therapeutics (ACRS) United States $0.165B 0.00
Innate Pharma SA (IPHYF) France $0.163B 0.00
Journey Medical (DERM) United States $0.162B 0.00
Galectin Therapeutics (GALT) United States $0.153B 0.00
Lyell Immunopharma (LYEL) United States $0.142B 0.00
Lexeo Therapeutics (LXEO) United States $0.140B 0.00
Achieve Life Sciences (ACHV) Canada $0.132B 0.00
Avita Medical (RCEL) United States $0.131B 0.00
VAXART, INC (VXRT) United States $0.128B 0.00
Inhibikase Therapeutics (IKT) United States $0.123B 0.00
Korro Bio (KRRO) United States $0.119B 0.00
Protara Therapeutics (TARA) United States $0.118B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.117B 0.00
Cardiol Therapeutics (CRDL) Canada $0.111B 0.00
Champions Oncology (CSBR) United States $0.108B 17.68
Corbus Pharmaceuticals Holdings (CRBP) United States $0.097B 0.00
Cassava Sciences (SAVA) United States $0.094B 0.00
Unicycive Therapeutics (UNCY) United States $0.088B 0.00
Nutriband (NTRB) United States $0.087B 0.00
Arch Biopartners (ACHFF) Canada $0.086B 0.00
Dominari Holdings (DOMH) United States $0.085B 0.00
Fractyl Health (GUTS) United States $0.083B 0.00
Pyxis Oncology (PYXS) United States $0.079B 0.00
ESSA Pharma (EPIX) Canada $0.077B 0.00
Surrozen (SRZN) United States $0.076B 0.00
Vivani Medical (VANI) United States $0.075B 0.00
Wellgistics Health (WGRX) United States $0.073B 0.00
Inotiv (NOTV) United States $0.067B 0.00
Assertio Holdings (ASRT) United States $0.061B 0.00
PMV Pharmaceuticals (PMVP) United States $0.060B 0.00
Rafael Holdings (RFL) United States $0.059B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.059B 0.00
Metagenomi (MGX) United States $0.058B 0.00
NRx Pharmaceuticals (NRXP) United States $0.056B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.055B 0.00
Avalo Therapeutics (AVTX) United States $0.054B 0.00
Gain Therapeutics (GANX) United States $0.054B 0.00
Telomir Pharmaceuticals (TELO) United States $0.052B 0.00
Context Therapeutics (CNTX) United States $0.052B 0.00
Century Therapeutics (IPSC) United States $0.051B 0.00
Prelude Therapeutics (PRLD) United States $0.049B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.049B 36.67
Klotho Neurosciences (KLTO) United States $0.047B 0.00
Mural Oncology (MURA) Ireland $0.042B 0.00
Karyopharm Therapeutics (KPTI) United States $0.040B 0.00
ElectroCore (ECOR) United States $0.040B 0.00
Iterum Therapeutics (ITRM) Ireland $0.039B 0.00
Acrivon Therapeutics (ACRV) United States $0.039B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.038B 0.00
Jupiter Neurosciences (JUNS) United States $0.037B 0.00
PolyPid (PYPD) Israel $0.036B 0.00
SCYNEXIS (SCYX) United States $0.029B 0.00
China SXT Pharmaceuticals (SXTC) China $0.029B 0.00
Enlivex Therapeutics (ENLV) Israel $0.028B 0.00
Tempest Therapeutics (TPST) United States $0.026B 0.00
FibroGen (FGEN) United States $0.022B 0.00
Natural Alternatives (NAII) United States $0.021B 0.00
DURECT (DRRX) United States $0.020B 0.00
BioVie (BIVI) United States $0.020B 0.00
Relmada Therapeutics (RLMD) United States $0.020B 0.00
BioLineRx (BLRX) Israel $0.019B 0.00
Carisma Therapeutics (CARM) United States $0.018B 0.00
Mannatech (MTEX) United States $0.017B 0.00
Vivos Therapeutics (VVOS) United States $0.017B 0.00
Lipocine (LPCN) United States $0.017B 0.00
Lyra Therapeutics (LYRA) United States $0.017B 0.00
CASI Pharmaceuticals (CASI) China $0.017B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.016B 0.00
VYNE Therapeutics (VYNE) United States $0.016B 0.00
Ernexa Therapeutics (ERNA) United States $0.015B 0.00
ProPhase Labs (PRPH) United States $0.015B 0.00
Citius Pharmaceuticals (CTXR) United States $0.014B 0.00
TherapeuticsMD (TXMD) United States $0.014B 0.00
Cosmos Health (COSM) United States $0.013B 0.00
Minerva Neurosciences (NERV) United States $0.013B 2.20
Scienture Holdings (SCNX) United States $0.012B 0.00
Phio Pharmaceuticals (PHIO) United States $0.011B 0.00
Mangoceuticals (MGRX) United States $0.010B 0.00
Ainos (AIMD) United States $0.010B 0.00
GlycoMimetics (CBIO) United States $0.010B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.009B 0.00
Talphera (TLPH) United States $0.009B 0.00
Traws Pharma (TRAW) United States $0.009B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.008B 0.00
Alaunos Therapeutics (TCRT) United States $0.008B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Indaptus Therapeutics (INDP) United States $0.007B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.007B 0.00
TransCode Therapeutics (RNAZ) United States $0.006B 0.00
Incannex Healthcare (IXHL) Australia $0.006B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
InMed Pharmaceuticals (INM) Canada $0.005B 0.00
Redhill Biopharma (RDHL) Israel $0.004B 0.00
SHINECO (SISI) China $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
CERo Therapeutics Holdings (CERO) United States $0.004B 0.00
SciSparc (SPRC) Israel $0.004B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Plus Therapeutics (PSTV) United States $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
PainReform (PRFX) Israel $0.003B 0.00
Aditxt (ADTX) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.003B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Conduit Pharmaceuticals (CDT) United States $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
MEI Pharma (MEIP) United States $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00